Juvenile-onset dentatorubral-pallidoluysian atrophy with recurrent deterioration and recovery of cognitive and motor function: A case report
Background Dentatorubral-pallidoluysian atrophy (DRPLA) is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the ATN1 gene. Juvenile-onset DRPLA typically presents with ataxia, myoclonus, epilepsy, and progressive deterioration. However, large-amplitude fluctuations in neurological status have rarely been reported. Case presentation We report a 10-year-old Japanese boy with juvenile-onset DRPLA who exhibited an atypical clinical course characterized by recurrent episodes of marked neurological deterioration followed by improvement. From age 4, he developed periodic brief leg stiffening. From age 5, he experienced recurrent episodes lasting several weeks that included drooling, brief hand drops, and brief leg stiffening. Around age 6, prominent neurological fluctuations recurred approximately every 3 months. During these episodes, myoclonic seizures increased, responsiveness and verbal output progressively decreased, and he eventually became unable to maintain a sitting position without support and lost verbal output. These periods generally lasted several weeks, followed by gradual improvement with regained speech and the ability to walk with assistance, apparently independent of major antiseizure medication (ASM) modifications. His neurological condition subsequently worsened, and by age 8 he became continuously bedridden and exhibited high-amplitude generalized spike-and-wave discharges on electroencephalography (EEG). After discontinuation of topiramate and perampanel, both neurological function and EEG findings markedly improved. He regained independent ambulation and speech, with no recurrence of epileptic seizures for 2 years. Discussion/Conclusion This case illustrates a clinical course characterized by large-amplitude, recurrent fluctuations in neurological status followed by ASM-related deterioration. Careful assessment is needed to avoid misattributing potentially reversible ASM-related adverse effects to irreversible disease progression.
Authors
- Tokito Yamaguchi
- Kyoko Takano (ORCID: https://orcid.org/0000-0002-7283-1503)
- Katsumi Imai (ORCID: https://orcid.org/0000-0001-8438-9284)
- Mitsuhiro Miyashita (ORCID: https://orcid.org/0000-0002-7798-1834)
- Ryojun Takeda (ORCID: https://orcid.org/0000-0003-1654-9463)
- Ryosuke Suzui
- Mitsuo Motobayashi (ORCID: https://orcid.org/0000-0003-3412-6819)
- Shino Shimada (ORCID: https://orcid.org/0000-0001-5525-7362)
- Yu Tsuyusaki (ORCID: https://orcid.org/0000-0003-2993-6526)
- Yukitoshi Takahashi (ORCID: https://orcid.org/0000-0002-1922-8967)
- Satoshi Mizutani (ORCID: https://orcid.org/0000-0002-4321-5357)
- Hideyuki Ohtani
- Manami Yabe
Institutions
- National Epilepsy Center (JP)
- National Center for Global Health and Medicine (JP)
- Shinshu University Hospital (JP)
- Nagano Children's Hospital (JP)
- Kashiwa Municipal Hospital (JP)
Publication Details
- Journal
- Brain and Development Case Reports
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1016/j.bdcasr.2026.100170
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00